Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Product quality issue? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Product quality issue have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.0% of all adverse event reports for DOXORUBICIN.

18
Reports of Product quality issue with DOXORUBICIN
0.0%
of all DOXORUBICIN reports
1
Deaths
4
Hospitalizations

How Dangerous Is Product quality issue From DOXORUBICIN?

Of the 18 reports, 1 (5.6%) resulted in death, 4 (22.2%) required hospitalization, and 2 (11.1%) were considered life-threatening.

Is Product quality issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Product quality issue?

ETONOGESTREL (4,651) ALBUTEROL (4,466) TIOTROPIUM (3,821) MOMETASONE FUROATE (3,406) LIDOCAINE (3,126) FLUTICASONE\SALMETEROL (2,986) FORMOTEROL\MOMETASONE FUROATE (2,458) FENTANYL (2,450) NICOTINE (1,987) EXENATIDE (1,839)

Which DOXORUBICIN Alternatives Have Lower Product quality issue Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Product quality issue Reports All Drugs Causing Product quality issue DOXORUBICIN Demographics